04:36 PM EST, 12/12/2024 (MT Newswires) -- Vir Biotechnology ( VIR ) said Thursday that the US Food and Drug Administration granted breakthrough therapy designation to tobevibart and elebsiran for the treatment of chronic hepatitis delta.

The European Medicines Agency also gave priority medicine designation to tobevibart and elebsiran, according to the company.

These designations are backed by safety and efficacy data from the phase 2 Solstice study, Vir added.

Shares of Vir Biotechnology ( VIR ) were up nearly 4% in after-hours activity.